Rain Oncology (NASDAQ:RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ...
The latest price target for Rain Enhancement (NASDAQ:RAIN) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $1.00 expecting RAIN to fall to within 12 months (a ...
The ionization rainfall company launched operations at its first U.S. site. The project gives Colorado its inaugural warm weather modification program at a time of persistent drought conditions across ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a ...
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology to provide additional rainfall for industries, supranational ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results